Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group

Published on Mar 1, 2015in Lancet Oncology33.752
· DOI :10.1016/S1470-2045(14)70409-7
Saro H. Armenian36
Estimated H-index: 36
(City of Hope National Medical Center),
Melissa M. Hudson104
Estimated H-index: 104
(St. Jude Children's Research Hospital)
+ 14 AuthorsLeontien C. M. Kremer52
Estimated H-index: 52
(Boston Children's Hospital)
Sources
Abstract
Summary Survivors of childhood cancer treated with anthracycline chemotherapy or chest radiation are at an increased risk of developing congestive heart failure. In this population, congestive heart failure is well recognised as a progressive disorder, with a variable period of asymptomatic cardiomyopathy that precedes signs and symptoms. As a result, several clinical practice guidelines have been developed independently to help with detection and treatment of asymptomatic cardiomyopathy. These guidelines differ with regards to definitions of at-risk populations, surveillance modality and frequency, and recommendations for interventions. Differences between these guidelines could hinder the effective implementation of these recommendations. We report on the results of an international collaboration to harmonise existing cardiomyopathy surveillance recommendations using an evidence-based approach that relied on standardised definitions for outcomes of interest and transparent presentation of the quality of the evidence. The resultant recommendations were graded according to the quality of the evidence and the potential benefit gained from early detection and intervention.
Download
📖 Papers frequently viewed together
2,464 Citations
1,047 Citations
200930.22BMJ
743 Citations
References141
Newest
#1Elske SieswerdaH-Index: 10
#2Elvira C. van DalenH-Index: 28
Last. Daniel K. L. Cheuk (HKU: University of Hong Kong)H-Index: 24
view all 6 authors...
Background Anthracyclines are frequently used chemotherapeutic agents for childhood cancer that can cause cardiotoxicity during and after treatment. Although several medical interventions in adults with symptomatic or asymptomatic cardiac dysfunction due to other causes are beneficial, it is not known if the same treatments are effective for childhood cancer patients and survivors with anthracycline-induced cardiotoxicity. This review is an update of a previously published Cochrane review. Objec...
44 CitationsSource
10.6k CitationsSource
#1Jennifer M. Yeh (Harvard University)H-Index: 17
#2Anju Nohria (Harvard University)H-Index: 39
Last. Lisa Diller (Harvard University)H-Index: 67
view all 3 authors...
Background Childhood cancer survivors treated with cardiotoxic therapies are recommended to undergo routine cardiac assessment every 1 to 5 years, yet the long-term benefits are uncertain.
65 CitationsSource
#1F. Lennie Wong (City of Hope National Medical Center)H-Index: 21
#2Smita Bhatia (City of Hope National Medical Center)H-Index: 93
Last. Saro H. Armenian (City of Hope National Medical Center)H-Index: 36
view all 13 authors...
Abstract Childhood cancer survivors treated with anthracyclines are at high risk for asymptomatic left ventricular dysfunction (ALVD), subsequent heart failure, and death. The consensus-based Children's Oncology Group (COG) Long-Term Follow-up Guidelines recommend lifetime echocardiographic screening for ALVD. To evaluate the efficacy and cost-effectiveness of the COG guidelines and to identify more cost-effective screening strategies. Simulation of life histories using Markov health states. Chi...
81 CitationsSource
#2Toana Kawashima (Fred Hutchinson Cancer Research Center)H-Index: 22
Last. Kevin C. Oeffinger (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 87
view all 9 authors...
Purpose The first generation of childhood cancer survivors is now aging into their fourth and fifth decades of life, yet health risks across the aging spectrum are not well established. Methods Analyses included 14,359 5-year survivors from the Childhood Cancer Survivor Study, who were first diagnosed when they were younger than 21 years old and who received follow-up for a median of 24.5 years after diagnosis (range, 5.0 to 39.3 years) along with 4,301 of their siblings. Among the survivors, 5,...
310 CitationsSource
#1Steven E. LipshultzH-Index: 113
#2M. Jacob AdamsH-Index: 20
Last. James D. WilkinsonH-Index: 52
view all 18 authors...
Cancer is diagnosed in >12 000 children and adolescents in the United States each year.1 Progress in cancer therapeutics over the past 40 years has remarkably improved survival rates for most childhood malignancies. For all pediatric cancers, 5-year survival increased from 58% for children diagnosed between 1975 and 1977 to 82% for those diagnosed between 1999 and 2006.2 In the United States, this success translates into >325 000 survivors of childhood cancer, of whom 24% are now >30 years from ...
303 CitationsSource
#1Clyde W. YancyH-Index: 121
#2Mariell JessupH-Index: 77
Last. Bruce L. Wilkoff (Heart Rhythm Society)H-Index: 88
view all 24 authors...
Jeffrey L. Anderson, MD, FACC, FAHA, Chair; Alice K. Jacobs, MD, FACC, FAHA, Immediate Past Chair[‡‡][1]; Jonathan L. Halperin, MD, FACC, FAHA, Chair-Elect; Nancy M. Albert, PhD, CCNS, CCRN, FAHA; Biykem Bozkurt, MD, PhD, FACC, FAHA; Ralph G. Brindis, MD, MPH, MACC; Mark A. Creager, MD, FACC,
10.3k CitationsSource
#1Gregory T. Armstrong (St. Jude Children's Research Hospital)H-Index: 63
#2Kevin C. Oeffinger (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 87
Last. Lillian R. Meacham (Emory University)H-Index: 28
view all 15 authors...
Purpose To evaluate the relative contribution of modifiable cardiovascular risk factors on the development of major cardiac events in aging adult survivors of childhood cancer. Patients and Methods Among 10,724 5-year survivors (median age, 33.7 years) and 3,159 siblings in the Childhood Cancer Survivor Study, the prevalence of hypertension, diabetes mellitus, dyslipidemia, and obesity was determined, along with the incidence and severity of major cardiac events such as coronary artery disease, ...
345 CitationsSource
#1Saro H. Armenian (City of Hope National Medical Center)H-Index: 36
#2Yan Ding (City of Hope National Medical Center)H-Index: 3
Last. Smita Bhatia (City of Hope National Medical Center)H-Index: 93
view all 11 authors...
Summary Haematopoietic cell transplantation (HCT) survivors are at increased risk for developing congestive heart failure (CHF), primarily due to pre-HCT exposure to anthracyclines. We examined the association between the development of CHF after HCT and polymorphisms in 16 candidate genes involved in anthracycline metabolism, iron homeostasis, anti-oxidant defence, and myocardial remodelling. A nested case-control study design was used. Cases (post-HCT CHF) were identified from 2950 patients wh...
74 CitationsSource
#1Megan Hoffman (UMN: University of Minnesota)H-Index: 2
#2Daniel A. MulrooneyH-Index: 32
Last. Kirsten K. NessH-Index: 84
view all 6 authors...
Purpose Childhood cancer survivors (CCSs) are at risk for physical disability. The aim of this investigation was to characterize and compare physical performance among CCSs and a group of siblings age < 18 years and determine if diagnosis, treatment, and physical activity levels were associated with lower performance scores. Methods CCSs ≥ 5 years from diagnosis and a sibling comparison group were recruited and evaluated for strength, mobility, and fitness. Physical performance measures were com...
85 CitationsSource
Cited By261
Newest
#1Caitlin W. Elgarten (Children's Hospital of Philadelphia)H-Index: 3
#2Andrew C. Wood (University of Auckland)H-Index: 13
Last. Soheil Meshinchi (Fred Hutchinson Cancer Research Center)H-Index: 57
view all 16 authors...
Background null High-risk pediatric acute myeloid leukemia confers a poor prognosis, and alternative strategies are needed to improve outcomes. We hypothesized that intensifying induction on the AAML1031 clinical trial would improve outcomes compared to the predecessor trial AAML0531. null Methods null Patients on AAML0531 received cytarabine (1600 mg/m2 )/daunorubicin (150 mg/m2 )/etoposide (ADE) for induction II and patients on AAML1031 received mitoxantrone (48 mg/m2 )/cytarabine (8000 mg/m2 ...
Source
#1Sumit Gupta (U of T: University of Toronto)H-Index: 25
#2Sarah Alexander (U of T: University of Toronto)H-Index: 30
Last. Paul C. NathanH-Index: 52
view all 8 authors...
Survival disparities by locus of care (LOC; paediatric versus adult) among adolescents and young adults (AYA) with acute lymphoblastic leukaemia (ALL) are well documented. Whether similar disparities exist among AYA with aggressive mature B-cell non-Hodgkin lymphoma (B-NHL) is unknown. We identified all Ontario, Canada AYA aged 15-21 years at diagnosis of B-NHL between 1992 and 2012. Demographic, disease, treatment and outcome data were chart abstracted. The impact of LOC on event-free (EFS) and...
Source
#1Natalie Bradford (QUT: Queensland University of Technology)H-Index: 18
#2Erin Pitt (QUT: Queensland University of Technology)
Last. Kimberly Alexander (QUT: Queensland University of Technology)H-Index: 10
view all 6 authors...
Purpose: The numbers of adolescent and young adult (AYA) survivors of childhood cancer are exponentially growing. To ensure suitable services are available to meet the needs of this growing populat...
Source
#1Benedikte Kristensen (UCPH: University of Copenhagen)H-Index: 1
#2Rikke Sand AndersenH-Index: 13
Last. Claire Friedemann Smith (Region Zealand)
view all 5 authors...
For the past decade, within family medicine there has been a focus on cultivating doctors gut feelings as ‘a way of knowing’ in cancer diagnostics. In this paper, building on interviews with family doctors in Oxford shire, UK we explore the embodied and temporal dimensions of clinical reasoning and how the cultivation of doctors’ gut feelings is related to hierarchies of medical knowledge, professional training, and doctors’ fears of litigation. Also, we suggest that the introduction of gut feel...
Source
#1Claire Fraley (Anschutz Medical Campus)
#2Sarah A. Milgrom (Anschutz Medical Campus)
Last. Shelley D. Miyamoto (Anschutz Medical Campus)H-Index: 20
view all 6 authors...
Cardiotoxicity is a well-recognized late effect among childhood cancer survivors. With various pediatric cancers becoming increasingly curable, it is imperative to understand the disease burdens that survivors may face in the future. In order to prevent or mitigate cardiovascular complications, we must first understand the mechanistic underpinnings. This review will examine the underlying mechanisms of cardiotoxicity that arise from traditional antineoplastic chemotherapies, radiation therapy, h...
Source
#1Carmen Bergom (WashU: Washington University in St. Louis)H-Index: 14
#2Julie A. Bradley (UF: University of Florida)H-Index: 14
Last. Joshua D. Mitchell (WashU: Washington University in St. Louis)H-Index: 15
view all 7 authors...
Abstract Radiation therapy is an important component of cancer therapy for many malignancies. With improvements in cardiac-sparing techniques, radiation-induced cardiac dysfunction has decreased bu...
Source
#1Yehia Saleh (MSU: Michigan State University)H-Index: 6
#2Ola Abdelkarim (MSU: Michigan State University)H-Index: 3
Last. George S. Abela (MSU: Michigan State University)H-Index: 35
view all 4 authors...
: Anthracycline is a mainstay in treatment of many cancers including lymphoma and breast cancer among many others. However, anthracycline treatment can be cardiotoxic. Although anthracycline-induced cardiotoxicity is dose dependent, it can also occur early at the onset of treatment and even up to several years following completion of treatment. This review article focuses on the understanding of mechanisms of anthracycline-induced cardiotoxicity, the treatments, and recommended follow-up and pre...
14 CitationsSource
#1George Makavos (UoA: National and Kapodistrian University of Athens)H-Index: 10
#2Ignatios Ikonomidis (UoA: National and Kapodistrian University of Athens)H-Index: 49
Last. Michel Noutsias (MLU: Martin Luther University of Halle-Wittenberg)H-Index: 36
view all 8 authors...
Cancer therapeutics induced cardiotoxicity has emerged as an important factor of long-term adverse cardiovascular outcomes in survivors of various malignant diseases. Early detection of myocardial injury in the setting of cancer treatment is important for the initiation of targeted cardioprotective therapy, in order to prevent irreversible cardiac dysfunction and heart failure, while not withholding a potentially life-saving cancer therapy. Cardiac imaging techniques including echocardiography, ...
2 CitationsSource
#1Suman Shrestha (University of Texas MD Anderson Cancer Center)H-Index: 1
#2James E. Bates (Emory University)H-Index: 1
Last. Bradford S. Hoppe (Mayo Clinic)H-Index: 29
view all 20 authors...
BACKGROUND AND PURPOSE We previously evaluated late cardiac disease in long-term survivors in the Childhood Cancer Survivor Study (CCSS) based on heart radiation therapy (RT) doses estimated from an age-scaled phantom with a simple atlas-based heart model (HAtlas). We enhanced our phantom with a high-resolution CT-based anatomically realistic and validated age-scalable cardiac model (HHybrid). We aimed to evaluate how this update would impact our prior estimates of RT-related late cardiac diseas...
Source
Last. Riccardo Haupt (Istituto Giannina Gaslini)H-Index: 44
view all 23 authors...
Abstract null null Background null Long-term follow-up (LTFU) care for childhood, adolescent, and young adult (CAYA) cancer survivors is essential to preserve health and quality of life (QoL). Evidence-based guidelines are needed to inform optimal surveillance strategies, but many topics are yet to be addressed by the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG). Therefore, the PanCareFollowUp Recommendations Working Group collaborated with stakeholders to ...
Source